Education
About Us
Working with TipRanks
Follow Us
ANI Pharmaceuticals Inc (ANIP)
NASDAQ:ANIP
Total Valuation
ANI Pharmaceuticals has a market cap or net worth of $1.90B. The enterprise value is $2.29B.
Market Cap$1.90B
Enterprise Value$2.29B
Share Statistics
ANI Pharmaceuticals has 22,458,168 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22,458,168
Owned by Insiders8.49%
Owned by Institutions22.46%
Financial Efficiency
ANI Pharmaceuticals’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is 0.04%.
Return on Equity (ROE)-0.04
Return on Assets (ROA)-0.01
Return on Invested Capital (ROIC)0.04%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee684.92K
Profits Per Employee-20.65K
Employee Count897
Asset Turnover0.48
Inventory Turnover1.83
Valuation Ratios
The current PE Ratio of ANI Pharmaceuticals is 51.7. ANI Pharmaceuticals’s PEG ratio is 0.28.
PE Ratio51.7
PS Ratio1.74
PB Ratio2.49
Price to Fair Value2.49
Price to FCF22.69
Price to Operating Cash Flow12.04
PEG Ratio0.28
Income Statement
In the last 12 months, ANI Pharmaceuticals had revenue of 614.38M and earned -18.52M in profits. Earnings per share was -1.04.
Revenue614.38M
Gross Profit364.17M
Operating Income584.00K
Pretax Income-22.21M
Net Income-18.52M
EBITDA63.12M
Earnings Per Share (EPS)-1.04
Cash Flow
In the last 12 months, operating cash flow was 170.72M and capital expenditures -35.40M, giving a free cash flow of 135.32M billion.
Operating Cash Flow170.72M
Free Cash Flow135.32M
Free Cash Flow per Share6.03
Dividends & Yields
ANI Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.50
52-Week Price Change46.62%
50-Day Moving Average89.93
200-Day Moving Average74.83
Relative Strength Index (RSI)45.47
Average Volume (3m)439.69K
Important Dates
ANI Pharmaceuticals upcoming earnings date is Feb 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateFeb 26, 2026
Ex-Dividend Date―
Financial Position
ANI Pharmaceuticals as a current ratio of 2.72, with Debt / Equity ratio of 73.29%
Current Ratio2.72
Quick Ratio2.02
Debt to Market Cap0.58
Net Debt to EBITDA6.05
Interest Coverage Ratio0.03
Taxes
In the past 12 months, ANI Pharmaceuticals has paid -3.69M in taxes.
Income Tax-3.69M
Effective Tax Rate0.17
Enterprise Valuation
ANI Pharmaceuticals EV to EBITDA ratio is 19.55, with an EV/FCF ratio of 32.87.
EV to Sales2.52
EV to EBITDA19.55
EV to Free Cash Flow32.87
EV to Operating Cash Flow24.17
Balance Sheet
ANI Pharmaceuticals has $262.61M in cash and marketable securities with $322.63M in debt, giving a net cash position of -$60.02M billion.
Cash & Marketable Securities$262.61M
Total Debt$322.63M
Net Cash-$60.02M
Net Cash Per Share-$2.67
Tangible Book Value Per Share-$8.97
Margins
Gross margin is 57.95%, with operating margin of 0.10%, and net profit margin of -3.01%.
Gross Margin57.95%
Operating Margin0.10%
Pretax Margin-3.62%
Net Profit Margin-3.01%
EBITDA Margin12.88%
EBIT Margin1.86%
Analyst Forecast
The average price target for ANI Pharmaceuticals is $113.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$113.50
Price Target Upside33.77% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast48.87%
EPS Growth Forecast―